Felixvet Introduces Atipamezole Injection for Reversal of Sedation and Analgesia in Dogs

Felixvet – a Bio-equivalent generics companion animals products company from India, announced the commercial availability of Atipamezole Hydrochloride Injection, a sterile injectable solution indicated for the reversal of the sedative and analgesic effects of dexmedetomidine hydrochloride and medetomidine hydrochloride in dogs.

Atipamezole Hydrochloride Injection provides veterinarians with an FDA-approved option to support recovery following sedation procedures and expands Felixvet’s growing portfolio of companion animal pharmaceuticals.

Atipamezole Hydrochloride Injection is indicated for the reversal of the sedative and analgesic effects of dexmedetomidine hydrochloride and medetomidine hydrochloride in dogs. The product is intended for intramuscular administration and is designed to support recovery following the use of these commonly utilized sedative agents.

Atipamezole Hydrochloride Injection is available as a 5.0 mg/mL sterile injectable solution supplied in a 10 mL multi-dose vial.

The product is approved for intramuscular use in dogs and is therapeutically equivalent to the pioneer product, providing the same safety and efficacy profile. As a reversal agent, Atipamezole Hydrochloride Injection serves as an important component of veterinary sedation protocols by helping veterinarians manage patient recovery following sedation procedures.

Felixvet continues to expand its portfolio of FDA-approved companion animal pharmaceuticals, supporting veterinarians and distribution partners with high-quality, bio-equivalent treatment options across key therapeutic categories.